TW252044B
(fr)
*
|
1992-08-10 |
1995-07-21 |
Boehringer Ingelheim Kg |
|
US5877179A
(en)
*
|
1992-09-29 |
1999-03-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
|
AU6781194A
(en)
*
|
1993-05-03 |
1994-11-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
|
DE4316576A1
(de)
*
|
1993-05-18 |
1994-11-24 |
Boehringer Ingelheim Kg |
Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
|
US5646156A
(en)
*
|
1994-04-25 |
1997-07-08 |
Merck & Co., Inc. |
Inhibition of eosinophil activation through A3 adenosine receptor antagonism
|
US5591776A
(en)
|
1994-06-24 |
1997-01-07 |
Euro-Celtique, S.A. |
Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
|
GB9415529D0
(en)
|
1994-08-01 |
1994-09-21 |
Wellcome Found |
Phenyl xanthine derivatives
|
JP2001523213A
(ja)
|
1994-12-13 |
2001-11-20 |
ユーロ−セルティーク,エス.エイ. |
三置換チオキサンチン類
|
CA2206287C
(fr)
*
|
1994-12-13 |
2001-03-20 |
Mark Chasin |
Aryle thioxanthines
|
US5864037A
(en)
|
1996-06-06 |
1999-01-26 |
Euro-Celtique, S.A. |
Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
|
GB9623859D0
(en)
*
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
US5786360A
(en)
*
|
1996-11-19 |
1998-07-28 |
Link Technology Incorporated |
A1 adenosine receptor antagonists
|
GB9703044D0
(en)
*
|
1997-02-14 |
1997-04-02 |
Glaxo Group Ltd |
Phenyl xanthine esters and amides
|
US6248746B1
(en)
|
1998-01-07 |
2001-06-19 |
Euro-Celtique S.A. |
3-(arylalkyl) xanthines
|
WO1999031101A1
(fr)
*
|
1997-12-17 |
1999-06-24 |
University Of South Florida |
Antagonistes du recepteur de l'adenosine presentant une bioactivite amelioree
|
DE19816857A1
(de)
*
|
1998-04-16 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
AU4980999A
(en)
|
1998-07-10 |
2000-02-01 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
A3 adenosine receptor antagonists
|
GB9817623D0
(en)
|
1998-08-13 |
1998-10-07 |
Glaxo Group Ltd |
Pharmaceutical compounds
|
BR0015545A
(pt)
|
1999-11-12 |
2002-08-06 |
Biogen Inc |
Policicloalquilpurinas como antagonistas dos receptores para adenosina
|
PT1230241E
(pt)
|
1999-11-12 |
2007-05-31 |
Biogen Idec Inc |
Antagonistas do receptor de adenosina e métodos de fabrico e uso dos mesmos
|
DE60018216T2
(de)
*
|
1999-12-24 |
2006-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Kondensierte purinderivate
|
US7087589B2
(en)
|
2000-01-14 |
2006-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methanocarba cycloakyl nucleoside analogues
|
SI1368349T1
(sl)
*
|
2001-02-24 |
2007-06-30 |
Boehringer Ingelheim Pharma |
Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
|
UA80258C2
(en)
*
|
2001-09-06 |
2007-09-10 |
Biogen Inc |
Methods of treating pulmonary disease
|
EP1521584A1
(fr)
|
2002-06-17 |
2005-04-13 |
Glaxo Group Limited |
Agonistes des recepteurs x du foie
|
US7407955B2
(en)
*
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10254304A1
(de)
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2004074247A2
(fr)
*
|
2003-02-19 |
2004-09-02 |
Endacea, Inc. |
Antagonistes du recepteur de l'adenosine a1
|
MXPA05011371A
(es)
|
2003-04-25 |
2005-12-01 |
Novacardia Inc |
Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
|
WO2005009343A2
(fr)
*
|
2003-06-06 |
2005-02-03 |
Endacea, Inc. |
Antagonistes du recepteur d'adenosine a1
|
JP2007506804A
(ja)
*
|
2003-06-09 |
2007-03-22 |
エンダセア, インコーポレイテッド |
A1アデノシンレセプターアンタゴニスト
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10355304A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2810295C
(fr)
|
2006-05-04 |
2017-11-14 |
Boehringer Ingelheim International Gmbh |
Une forme polymere de 1-((4-methyle-quinazoline-2-yl)methyle)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
JP2010500326A
(ja)
*
|
2006-08-08 |
2010-01-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病の治療のためのdpp−iv阻害剤としてのピロロ[3,2−d]ピリミジン
|
KR101610005B1
(ko)
*
|
2007-08-17 |
2016-04-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
|
WO2009086077A2
(fr)
|
2007-12-21 |
2009-07-09 |
Endacea, Inc. |
Antagonistes des récepteurs de l'adénosine a1
|
US7928259B2
(en)
*
|
2008-02-12 |
2011-04-19 |
Frx Polymers, Inc. |
Diaryl alkylphosphonates and methods for preparing same
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR101657960B1
(ko)
*
|
2008-08-15 |
2016-09-20 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
|
EP2344195A2
(fr)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Polythérapie pour le traitement du diabète et des états pathologiques apparentés
|
JP5334511B2
(ja)
*
|
2008-09-22 |
2013-11-06 |
日本精化株式会社 |
化粧料
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
EP2410855B1
(fr)
*
|
2009-03-26 |
2016-06-01 |
Mapi Pharma Limited |
Procédé de préparation d'alogliptine
|
CA2782179C
(fr)
|
2009-11-27 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Traitement de patients diabetiques genotypes par des inhibiteurs de dpp-iv tels que la linagliptine
|
WO2011068978A1
(fr)
|
2009-12-02 |
2011-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dérivés de méthanocarba-adénosine et conjugués de dendrimère de ceux-ci
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
ES2953123T3
(es)
|
2010-06-24 |
2023-11-08 |
Boehringer Ingelheim Int |
Terapia para la diabetes
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
EP2731947B1
(fr)
|
2011-07-15 |
2019-01-16 |
Boehringer Ingelheim International GmbH |
Quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement de la diabète type i et type ii
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP3685839A1
(fr)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
RU2643336C1
(ru)
*
|
2016-10-03 |
2018-01-31 |
Общество с Ограниченной Ответственностью "Компания "ЭЛТА" |
СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
|
CN109796453A
(zh)
*
|
2019-02-12 |
2019-05-24 |
南京纽邦生物科技有限公司 |
一种1,7-二甲基黄嘌呤的制备方法
|
EP4229059A1
(fr)
|
2020-10-15 |
2023-08-23 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Dérivés de xanthine substitués en position 3 utilisés comme modulateurs du récepteur mrgprx4
|